Phibro Animal Health Corporation Stock

Equities

PAHC

US71742Q1067

Pharmaceuticals

Market Closed - Nasdaq 04:00:00 2024-05-16 pm EDT 5-day change 1st Jan Change
17.98 USD -1.48% Intraday chart for Phibro Animal Health Corporation +1.58% +55.27%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Hours!
Take advantage of the offer
* See conditions on site
Sales 2024 * 1B Sales 2025 * 1.17B Capitalization 728M
Net income 2024 * 13M Net income 2025 * 29M EV / Sales 2024 * 0.96 x
Net Debt 2024 * 233M Net Debt 2025 * 463M EV / Sales 2025 * 1.02 x
P/E ratio 2024 *
54.5 x
P/E ratio 2025 *
25.1 x
Employees 1,920
Yield 2024 *
2.67%
Yield 2025 *
2.63%
Free-Float 49.9%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Phibro Animal Health Corporation, Q3 2024 Earnings Call, May 09, 2024
Earnings Flash (PAHC) PHIBRO ANIMAL HEALTH CORPORATION Posts Q3 EPS $0.31, vs. Street Est of $0.29 MT
Earnings Flash (PAHC) PHIBRO ANIMAL HEALTH CORPORATION Posts Q3 Revenue $263.2M, vs. Street Est of $253.7M MT
Phibro Animal Health Corporation Updates Earnings Guidance for the Year 2024 CI
Phibro Animal Health Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 CI
Phibro Animal Health Corporation Declares Quarterly Dividend, Payable on June 26, 2024 CI
Transcript : Phibro Animal Health Corporation - Special Call
Zoetis to Sell Medicated-Feed-Additive Portfolio to Phibro for $350 Million DJ
Zoetis to Sell Medicated Feed Additives Business to Phibro Animal Health for $350 Million MT
Zoetis to sell medicated feed additive portfolio to Phibro in $350 mln deal RE
Phibro Animal Health Corporation entered into a definitive agreement to acquire Medicated feed additive product portfolio, certain water soluble products and related assets of Zoetis Inc. for approximately $350 million. CI
Transcript : Phibro Animal Health Corporation Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 04:35 PM
Transcript : Phibro Animal Health Corporation Presents at Bank of America 2024 Animal Health Virtual Summit, Feb-29-2024 10:00 AM
Transcript : Phibro Animal Health Corporation, Q2 2024 Earnings Call, Feb 08, 2024
Earnings Flash (PAHC) PHIBRO ANIMAL HEALTH CORPORATION Posts Q2 EPS $0.33, vs. Street Est of $0.28 MT
More news

Latest transcript on Phibro Animal Health Corporation

1 day-1.48%
1 week+1.58%
Current month+7.66%
1 month+38.41%
3 months+48.96%
6 months+70.75%
Current year+55.27%
More quotes
1 week
17.61
Extreme 17.61
18.61
1 month
12.30
Extreme 12.3
18.61
Current year
10.04
Extreme 10.035
18.61
1 year
9.40
Extreme 9.4
18.61
3 years
9.40
Extreme 9.4
31.00
5 years
9.40
Extreme 9.4
33.97
10 years
9.40
Extreme 9.4
54.62
More quotes
Managers TitleAgeSince
Chief Executive Officer 77 68-12-31
Director of Finance/CFO 52 Feb. 08
Chief Operating Officer 60 08-04-30
Members of the board TitleAgeSince
Chief Executive Officer 77 68-12-31
Director/Board Member 77 08-04-30
Director/Board Member 63 10-06-30
More insiders
Date Price Change Volume
24-05-16 17.98 -1.48% 101,517
24-05-15 18.25 +0.22% 148,299
24-05-14 18.21 +0.55% 178,907
24-05-13 18.11 +3.19% 161,917
24-05-10 17.55 -0.85% 127,608

Delayed Quote Nasdaq, May 16, 2024 at 04:00 pm EDT

More quotes
Phibro Animal Health Corporation is a diversified animal health and mineral nutrition company. It develops, manufactures and markets a range of products for food and companion animals, including poultry, swine, beef and dairy cattle, aquaculture and dogs. It markets approximately 770 product lines in over 80 countries to approximately 4,000 customers. The Company has three segments. Animal Health segment develops, manufactures and markets about 270 product lines, including antibacterials, anticoccidials and related products; nutritional specialty products; and vaccines. Mineral Nutrition segment manufactures and markets approximately 420 formulations and concentrations of trace minerals, such as zinc, manganese, copper, iron and other compounds, with a focus on customers in North America. Performance Products segment manufactures and markets specialty ingredients for use in the personal care, industrial chemical and chemical catalyst industries, predominantly in the United States.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
UNDERPERFORM
Number of Analysts
4
Last Close Price
17.98 USD
Average target price
13.5 USD
Spread / Average Target
-24.92%
Consensus
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW